User:Mr. Ibrahem/Setmelanotide

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Setmelanotide
Clinical data
Trade namesImcivree
Other namesRM-493; BIM-22493; IRC-022493; N2-Acetyl-L-arginyl-L-cysteinyl-D-alanyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-L-cysteinamide, cyclic (2-8)-disulfide
AHFS/Drugs.comMonograph
License data
Routes of
administration		Subcutaneous
Legal status
Legal status
Identifiers
  • (4R,7S,10S,13R,16S,19R,22R)-22-[[(2S)-2-Acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carboxamide
Chemical and physical data
FormulaC49H68N18O9S2
Molar mass1117.32 g·mol−1
3D model (JSmol)
  • C[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C)C(=O)N)Cc2c[nH]c3c2cccc3)CCCN=C(N)N)Cc4ccccc4)Cc5cnc[nH]5
  • InChI=1S/C49H68N18O9S2/c1-26-41(70)63-37(20-30-22-55-25-59-30)46(75)64-35(18-28-10-4-3-5-11-28)44(73)62-34(15-9-17-57-49(53)54)43(72)65-36(19-29-21-58-32-13-7-6-12-31(29)32)45(74)66-38(40(50)69)23-77-78-24-39(47(76)60-26)67-42(71)33(61-27(2)68)14-8-16-56-48(51)52/h3-7,10-13,21-22,25-26,33-39,58H,8-9,14-20,23-24H2,1-2H3,(H2,50,69)(H,55,59)(H,60,76)(H,61,68)(H,62,73)(H,63,70)(H,64,75)(H,65,72)(H,66,74)(H,67,71)(H4,51,52,56)(H4,53,54,57)/t26-,33+,34+,35-,36+,37+,38+,39+/m1/s1
  • Key:HDHDTKMUACZDAA-PHNIDTBTSA-N

Setmelanotide, sold under the brand name Imcivree, is a medication used to treat specific genetic causes of obesity.[1][3] This includes significant pro-opiomelanocortin (POMC) deficiency, proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency, leptin receptor (LEPR) deficiency, and Bardet-Biedl syndrome (BBS).[1] It is used in those at least 6 years old.[3] It is given by injection under the skin.[1]

Common side effects include injection site reactions, increased skin pigmentation, headache, nausea, diarrhea, abdominal pain, and depression.[1] Other side effects may include sexual arousal and thoughts of suicide.[1] Use in not recommended in pregnancy or breast feeding.[1] It is a melanocortin 4 (MC4) receptor agonist.[1]

Setmelanotide was approved for medical use in the United States in 2020 and Europe in 2021.[1][3] In the United States it costs about 33,000 USD per month as of 2022.[4]

References[edit]

  1. ^ a b c d e f g h i j k l "Imcivree- setmelanotide solution". DailyMed. Archived from the original on 21 October 2021. Retrieved 25 December 2020.
  2. ^ "FDA approves first treatment for weight management for people with certain rare genetic conditions". U.S. Food and Drug Administration (FDA) (Press release). 27 November 2020. Archived from the original on 27 November 2020. Retrieved 27 November 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  3. ^ a b c d e "Imcivree EPAR". European Medicines Agency (EMA). 19 May 2021. Archived from the original on 23 July 2021. Retrieved 22 July 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  4. ^ "Imcivree". Archived from the original on 11 November 2022. Retrieved 3 November 2022.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Setmelanotide&oldid=1212091884"